Acivicin: a new glutamine antagonist in clinical trials.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000378:metabolism* / Q000627:therapeutic use / Q000633:toxicity; D000963:Antimetabolites / Q000378:metabolism* / Q000627:therapeutic use / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D005973:Glutamine / Q000037:antagonists & inhibitors*; D006207:Half-Life; D006801:Humans; D007555:Isoxazoles / Q000378:metabolism* / Q000627:therapeutic use / Q000633:toxicity; D007700:Kinetics; D007942:Leukemia, Experimental / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000378:metabolism; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D010080:Oxazoles / Q000378:metabolism*; D011687:Purines / Q000096:biosynthesis; D011743:Pyrimidines / Q000096:biosynthesis; D012513:Sarcoma, Experimental
D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D007555:Isoxazoles; D010080:Oxazoles; D011687:Purines; D011743:Pyrimidines; D005973:Glutamine; C006303:acivicin